Tiziana Life Sciences Ltd (TLSA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.93 (-3.75%), Market cap $0.18B, 52-week low–high $1.15 ~ $2.50.
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the U
Financial statements, price targets, institutional (13F) holdings and related news for Tiziana Life Sciences Ltd are updated in real time on BlackAll Trade.
Tiziana Life Sciences Ltd trades at $0.93 (-3.75%). Real-time quotes and charts are available on BlackAll Trade.
Tiziana Life Sciences Ltd has a market cap of about $0.18B.
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product cand